Cargando…
Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells
BACKGROUND: T cell-redirecting bispecific antibodies (BsAbs) are emerging as a potent cancer therapy that crosslinks tumor cells and T cells by simultaneously binding to tumor-associated antigen and CD3ε. However, immune inhibitory molecules can be remarkably upregulated after BsAbs treatment, leadi...
Autores principales: | Zhu, Mei, Wang, Hongmei, Zhou, Shujuan, Wei, Jia, Ding, Naiqing, Shao, Jie, Yu, Lixia, Feng, Zhenqing, Liu, Baorui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873023/ https://www.ncbi.nlm.nih.gov/pubmed/33574677 http://dx.doi.org/10.2147/OTT.S291086 |
Ejemplares similares
-
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation
por: Zhou, Shujuan, et al.
Publicado: (2021) -
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019) -
Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma
por: Zhou, Chong, et al.
Publicado: (2022) -
Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer
por: Zhang, Dinghu, et al.
Publicado: (2020) -
Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency
por: Bian, Xinyu, et al.
Publicado: (2016)